Home > Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks
Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks
Manuscript Number:
20-0134R1
Author(s):
Tobias Bittner, Kathleen Blondeau, Montserrat Carrasco-Triguero, David Clayton, Michael Dolton, Heather Guthrie, Lawrence S. Honig, Qinshu Lian, Helen Lin, Susanne Ostrowitzki, Angelica Quartino, Kaycee M. Sink, Jillian Smith
